Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Imunon, Inc.

Ticker
IMNN
Sector
Industry
Report date
November 15, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Imunon's ongoing clinical progress with IMNN-001, financial results for Q3 2026, and strategic asset sales.

Recent developments:
  • Imunon reported third quarter 2026 financial results including a net loss of $3.813 million and provided a business update on clinical progress [N1][N3].
  • The company held its Q3 2026 earnings call discussing clinical trial advancements and financial status [N2].
  • Imunon agreed to sell its ThermoDox assets to VoxelDox Therapeutics, Inc. for up to $16.5 million in milestones and royalties, subject to closing conditions [N4].
  • IMNN-001 Phase 3 OVATION 3 trial enrollment is ahead of plan, with a highlighted 14.7-month survival benefit reported [N6][N8].
  • The company secured $10 million in cash financing to advance the Phase 3 ovarian cancer trial of IMNN-001 [N7].
  • Imunon’s stock surged over 18% on positive biotech sector movement and company-specific news [N5].
Overview

Imunon, Inc. is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines using proprietary non-viral DNA delivery platforms. Its lead product candidate, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer. IMNN-001 delivers interleukin-12 and interferon gamma locally to the tumor site to stimulate a potent immune response while minimizing systemic toxicity. The company has completed Phase I and Phase II clinical trials and is currently conducting a Phase 3 trial (OVATION 3) for IMNN-001. Imunon has discontinued its PlaCCine and IMNN-101 vaccine programs and is selling its ThermoDox assets to VoxelDox Therapeutics, Inc. The company manufactures IMNN-001 at a single facility in Huntsville, Alabama, and relies on this site for clinical supply. Financially, Imunon reported a net loss of $3.75 million for Q3 2026 and held $4.04 million in cash as of September 30, 2026, with a current ratio of 1.38. The company secured $10 million in financing to support ongoing Phase 3 trials. Risks include reliance on the success of IMNN-001, manufacturing concentration, and uncertainties related to the ThermoDox asset sale [S1][S2][N1][N4][N6][N7][N8].

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Imunon, Inc. is a clinical-stage biotech company developing DNA-based immunotherapies, primarily IMNN-001 for advanced ovarian cancer, currently in Phase 3 trials. The company reported a net loss of $3.75 million for Q3 2026 and maintains liquidity with $4.04 million cash and a current ratio of 1.38 as of September 30, 2026. Imunon has discontinued other vaccine programs and agreed to sell its ThermoDox assets, with milestone-based consideration. Enrollment in the Phase 3 trial is ahead of plan, supported by recent financing. Risks include dependence on IMNN-001 success, manufacturing concentration, and execution risks related to asset sales [S2][N1][N3][N4][N6][N7][N8].

Scenarios for IMNN

Bull case model:

Imunon's lead candidate, IMNN-001, has demonstrated promising clinical signals including a 14.7-month survival benefit in ovarian cancer and positive Phase 2 data supporting progression to Phase 3 trials. The company's proprietary DNA delivery platform offers potential advantages in safety and efficacy through localized cytokine delivery. Successful completion of the OVATION 3 Phase 3 trial and regulatory approvals could validate the technology and open opportunities for broader applications. The recent $10 million financing and ahead-of-plan enrollment in Phase 3 trials support continued clinical advancement. The sale of non-core assets like ThermoDox may allow Imunon to focus resources on its lead program, potentially enhancing operational efficiency and value creation.

Bear case model:

Imunon is highly dependent on the success of a single product candidate, IMNN-001, with no other active programs to offset setbacks. Manufacturing is concentrated at a single facility, posing risks of supply disruption. The ThermoDox asset sale is contingent on the buyer raising funds, and consideration includes illiquid equity and milestone payments, which may not materialize. The company reported a net loss and limited cash reserves, which may constrain operations without additional financing. Clinical development risks, regulatory hurdles, and competitive pressures in ovarian cancer immunotherapy present significant challenges. Any delays or failures in clinical trials or manufacturing could materially harm the business.

Moat:

Imunon's moat is based on its proprietary non-viral DNA delivery technology platform, which enables localized delivery of therapeutic DNA plasmids with potentially improved safety and efficacy profiles compared to systemic therapies. The company's focus on DNA-based immunotherapy for ovarian cancer, particularly IMNN-001, leverages a differentiated approach combining immunotherapy with chemotherapy to enhance clinical outcomes. The platform's versatility and biocompatibility may provide competitive advantages in gene delivery. However, as a clinical-stage biotech with a single lead product candidate and manufacturing concentrated at one facility, the moat is contingent on successful clinical development, regulatory approvals, and commercialization. The discontinuation of other programs and asset sales indicate a narrowed focus, which may limit diversification benefits.

Risks overview
Risks summary
Imunon's biggest risk is its reliance on the success of a single clinical-stage product candidate, IMNN-001, combined with manufacturing concentration and financial constraints that could impact its ability to sustain operations and advance clinical development.
Risks details:

• Dependence on IMNN-001: The company is entirely dependent on the success of its lead product candidate IMNN-001. Any setback in this program could materially harm the business as there are no other active candidates to offset it [S2].
• Manufacturing Concentration: IMNN-001 is manufactured at a single facility in Huntsville, Alabama. Loss, damage, or regulatory non-compliance at this facility could interrupt clinical supply and delay development [S2].
• ThermoDox Asset Sale Uncertainty: The sale of ThermoDox assets to VoxelDox Therapeutics depends on VoxelDox raising at least $2.5 million. Consideration includes illiquid private stock and milestone payments, which carry execution and liquidity risks [S2][N4].
• Financial and Liquidity Risks: The company reported a net loss of $3.75 million for Q3 2026 and holds limited cash reserves. Ongoing operations depend on securing additional financing and managing cash effectively [S2][N3].
• Clinical Development Risks: Clinical trials for IMNN-001 face inherent risks including regulatory approval, patient enrollment, and demonstration of safety and efficacy. Any adverse outcomes could impact the company's prospects [S1][N2].

FINAL FORECAST FOR IMNN

Final take one line
Imunon, Inc. exhibits very high visibility with detailed disclosures on its DNA-based immunotherapy development, financials, and strategic asset sales.
Final take 12 to 24 month view

Business trends: Continued clinical advancement of IMNN-001 in ovarian cancer with positive survival data and focused portfolio after asset sales.
Execution milestones: Completion of Phase 3 OVATION 3 trial enrollment, successful ThermoDox asset sale, and securing financing to support operations.
Key risks: Dependence on a single product candidate, manufacturing concentration, financial constraints, and execution risks related to asset sales and clinical development.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines using non-viral DNA technology platforms, including TheraPlas® and PlaCCine® modalities [S1].
  • The lead clinical program is IMNN-001, a DNA-based immunotherapy for localized treatment of advanced ovarian cancer, currently in a Phase 3 clinical trial (OVATION 3) [S1].
  • IMNN-001 works by instructing the body to produce cancer-fighting molecules such as interleukin-12 and interferon gamma at the tumor site, aiming for a durable immune response [S1].
  • The company has completed multiple clinical trials including Phase I, Phase II (OVATION 2), and is advancing Phase 3 (OVATION 3) for IMNN-001 [S1].
  • IMNN-001 is administered intraperitoneally combined with chemotherapy, aiming to improve outcomes over chemotherapy alone by local delivery of IL-12 to reduce systemic toxicity [S1].
  • The company has discontinued its PlaCCine and IMNN-101 vaccine programs and agreed to sell its ThermoDox assets to VoxelDox Therapeutics, Inc. for up to $16.5 million in milestones plus royalties [N4][S2].
  • Imunon reported a net loss of approximately $3.75 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.64 [S2][N3].
  • As of September 30, 2026, Imunon had cash and cash equivalents of about $4.04 million and a current ratio of 1.38, indicating liquidity to support ongoing operations [S2].
  • The company manufactures IMNN-001 at a single facility in Huntsville, Alabama, which must comply with FDA cGMP requirements; loss or disruption at this facility could impact clinical supply [S2].
  • The sale of ThermoDox assets depends on VoxelDox raising at least $2.5 million; consideration includes illiquid private stock and milestone payments, which carry execution risk [S2].
  • Imunon highlights a 14.7-month survival benefit for IMNN-001 in ovarian cancer and reports that enrollment in the OVATION 3 Phase 3 trial is ahead of plan [N6][N8].
  • The company secured $10 million in cash financing to advance the Phase 3 ovarian cancer trial of IMNN-001 [N7].
  • Recent quarterly results and earnings call transcripts provide updates on clinical progress and financial status through Q3 2026 [N1][N2].
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
  • N2
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Imunon, Inc. Reports Third Quarter 2026 Financial Results and Provides Business Update | https://www.nasdaq.com/articles/imunon-inc-reports-third-quarter-2026-financial-results-and-provides-business-update
  • N2 | 2026-11-12 | www.nasdaq.com | Imunon (IMNN) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/imunon-imnn-q3-2026-earnings-call-transcript
  • N3 | 2026-11-12 | www.nasdaq.com | Imunon, Inc. Loss At -$3.813 Mln In Q3 | https://www.nasdaq.com/articles/imunon-inc-loss-3813-mln-q3
  • N4 | 2026-10-21 | www.nasdaq.com | Imunon, Inc. Agrees to Sell ThermoDox Assets to VoxelDox Therapeutics, Inc. for Up to $16.5 million in Milestones | https://www.nasdaq.com/articles/imunon-inc-agrees-sell-thermodox-assets-voxeldox-therapeutics-inc-165-million-milestones
  • N5 | 2026-10-21 | www.nasdaq.com | Biotech Stocks Move Higher: IMNN Surges Over 18%, HSCS Gains Over 13%, SXTC Rises 7% | https://www.nasdaq.com/articles/biotech-stocks-move-higher-imnn-surges-over-18-hscs-gains-over-13-sxtc-rises-7
  • N6 | 2026-09-24 | www.nasdaq.com | IMUNON Highlights 14.7-Month Survival Benefit For IMNN-001; OVATION 3 Enrollment Ahead Of Plan | https://www.nasdaq.com/articles/imunon-highlights-147-month-survival-benefit-imnn-001-ovation-3-enrollment-ahead-plan
  • N7 | 2026-08-12 | www.nasdaq.com | Imunon (IMNN) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/imunon-imnn-q2-2026-earnings-call-transcript
  • N8 | 2026-08-11 | www.nasdaq.com | IMUNON Advances OVATION 3 Trial Of IMNN-001; Enrollment Expected To Complete In 1H29 | https://www.nasdaq.com/articles/imunon-advances-ovation-3-trial-imnn-001-enrollment-expected-complete-1h29
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine